scholarly journals Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Tatsuya Fukuta ◽  
Tomohiro Asai ◽  
Takayuki Ishii ◽  
Hiroyuki Koide ◽  
Chiaki Kiyokawa ◽  
...  
2016 ◽  
Vol 57 (6) ◽  
pp. 950-953 ◽  
Author(s):  
H. Tsukada ◽  
M. Kanazawa ◽  
H. Ohba ◽  
S. Nishiyama ◽  
N. Harada ◽  
...  

Author(s):  
Wei-Chih Lin ◽  
Ya-Huei Chen ◽  
Shin-Yuan Gu ◽  
Hwei-Ling Shen ◽  
Kai-Chau Huang ◽  
...  

Abstract Plant CRM domain-containing proteins are capable of binding RNA to facilitate the splicing of group I or II introns in chloroplasts, but their functions in mitochondria are less clear. In the present study, Arabidopsis thaliana CFM6, a protein with a single CRM domain, was expressed in most plant tissues, particularly in flower tissues, and restricted to mitochondria. Mutation of CFM6 causes severe growth defects, including stunted growth, curled leaves, delayed embryogenesis, and pollen development. CFM6 functions specifically in the splicing of group II intron 4 of nad5, which encodes a subunit of mitochondrial complex I, as evidenced by the loss of nad5 intron 4 splicing and high accumulation of its pretranscripts in cfm6 mutants. The phenotypic and splicing defects of cfm6 were rescued in transgenic plants overexpressing 35S::CFM6-YFP. Splicing failure in cfm6 also led to the loss of complex I activity and to its improper assembly. Moreover, dysfunction of complex I induced the expression of proteins or genes involved in alternative respiratory pathways in cfm6. Collectively, CFM6, a previously uncharacterized CRM domain-containing protein, is specifically involved in the cis-splicing of nad5 intron 4 and plays a pivotal role in mitochondrial complex I biogenesis and normal plant growth.


2020 ◽  
pp. 0271678X2092814 ◽  
Author(s):  
Ayla Mansur ◽  
Eugenii A Rabiner ◽  
Hideo Tsukada ◽  
Robert A Comley ◽  
Yvonne Lewis ◽  
...  

Mitochondrial complex I (MC-I) is an essential regulator of brain bioenergetics and can be quantified in the brain using PET radioligand 18F-BCPP-EF. Here we evaluate the test–retest reproducibility of 18F-BCPP-EF in humans, and assess the use of a non-invasive quantification method (standardised uptake value ratio – SUVR). Thirty healthy volunteers had a 90-min dynamic 18F-BCPP-EF scan with arterial blood sampling, five of which received a second scan to be included in the test–retest analysis. Time-activity curves (TAC) were analysed using multilinear analysis 1 (MA1) and the two-tissue compartment model (2TC) to estimate volumes of distribution (VT). Regional SUVR-1 values were calculated from the 70 to 90-min TAC data using the centrum semiovale as a pseudo reference region, and compared to kinetic analysis-derived outcome measures. The mean absolute test–retest variability of VT ranged from 12% to 18% across regions. Both DVR-1and SUVR-1 had improved test–retest variability in the range 2%–7%. SUVR-1 was highly correlated with DVR-1 (r2 = 0.97, n = 30). In conclusion, 18F-BCPP-EF has suitable test–retest reproducibility and can be used to quantify MC-I in clinical studies.


2004 ◽  
Vol 1 (4) ◽  
pp. 316-322 ◽  
Author(s):  
Julie Defretin ◽  
Christophe Gleye ◽  
Diego Cortes ◽  
Xavier Franck ◽  
Reynald Hocquemiller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document